• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

How to De-Risk Drug Development from the Earliest Stages

Wednesday, June 05, 2024
Breakout Session
Business Development and Finance
23BC
Novel therapies often don’t meet their revenue expectations. In an environment where regulatory approvals are increasing, but funding is decreasing, how do biotech innovators prioritize decision-making from pre-clinical phases to set up clinical development for the best chance of commercial success? This session explores the business-critical actions at key milestones that ultimately determine a product’s value story. Through an informed perspective on the impact of market dynamics on early-stage development, experts will discuss critical steps for biotech sponsors to mitigate technical, safety, efficacy, and commercial risks, to maximize the probability of success. Focusing on pre-clinical and pre-proof of concept phases in product development, the panel will discuss 1) due diligence and early considerations for prioritizing assets and indications; 2) capital-efficient ways of generating preclinical and clinical data; 3) how to drive value, by quickly proving clinical differentiation; 4) how to translate science to clinical applications and communicate it to investors, investigators and regulators; and 5) the importance of building integrated evidence at the earliest stages of development to satisfy the needs of multiple stakeholders.
Speakers
Wyatt Gotbetter
Senior Vice President and Worldwide Head, Access Consulting
PAREXEL
Abhiram Rao, PhD
Director
EQT Life Sciences
Ned Wydysh
Vice President
Health Advances, LLC

Sponsored by:

parexel biotech
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS